EC145
Phase 3Small molecule
EC145 is one of 70 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Avastin
BBio-Thera Solutions
Phase 3
Femara
NovartisPhase 3
Votrient
NovartisPhase 3
Adriamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
H2 Receptor Antagonist
Merck & Co.Phase 3
IV Iron
PfizerPhase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
C141 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EC145. EMBL-EBI & Wellcome Sanger Institute.
- [4]